Victory Capital Management
ACOR

Victory Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Victory Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-50
Closed -$6K – 3490
2020
Q1 		$6K Buy
+50
New +$9.84K ﹤0.01% 3251
2019
Q4 		– Sell
-53
Closed -$18K – 3476
2019
Q3 		$18K Buy
+53
New +$28.8K ﹤0.01% 3089
2015
Q3 		– Sell
-11
Closed -$42K – 1729
2015
Q2 		$42K Buy
+11
New +$42.5K ﹤0.01% 1539

Other funds holding ACOR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Victory Capital Management's ACOR Position: Q2 2020 in Review

Victory Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2020, closing a stake of 50 shares — an estimated $6K sold.

Victory Capital Management first reported a position in ACOR in Q2 2015 and held it in 3 quarters. The position peaked at $42K in Q2 2015. 79 funds tracked by Wall St. Rank hold ACOR as of Q2 2020.

  • Victory Capital Management reported no remaining Acorda Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 50 Acorda Therapeutics shares in Q2 2020, an estimated $6K.
  • Victory Capital Management first reported a position in Acorda Therapeutics in Q2 2015 and held it in 3 quarters.
  • Victory Capital Management's Acorda Therapeutics position peaked at $42K in Q2 2015.
  • 79 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.